https://razorgenomics.com/publications/a-practical-molecular-assay-to-predict-survival-in-resected-non-squamous-non-small-cell-lung-cancer-development-and-international-studies/ 2012-01-01T16:59:00+00:00 https://razorgenomics.com/publications/analytical-validation-of-a-practical-molecular-assay-prognostic-of-survival-in-nonsquamous-non-small-cell-lung-cancer/ 2013-01-01T17:00:00+00:00 https://razorgenomics.com/publications/prognostic-molecular-assay-might-improve-identification-of-patients-at-risk-for-recurrence-in-early-stage-non-small-cell-lung-cancer/ 2014-01-01T17:00:00+00:00 https://razorgenomics.com/publications/the-impact-of-a-fourteen-gene-molecular-assay-on-physician-treatment-decisions-in-non-small-cell-lung-cancer/ 2015-01-01T17:00:00+00:00 https://razorgenomics.com/publications/adjuvant-chemotherapy-decisions-based-on-molecular-risk-status-improves-outcomes-in-early-stage-non-small-cell-lung-cancer/ 2017-01-01T17:00:00+00:00 https://razorgenomics.com/publications/incorporation-of-a-molecular-prognostic-classifier-improves-conventional-non-small-cell-lung-cancer-staging-2/ 2018-01-01T16:58:00+00:00 https://razorgenomics.com/publications/expanded-data-confirm-molecular-testing-identifies-lung-adenocarcinoma-patients-including-stage-ia-who-benefit-from-adjuvant-chemotherapy/ 2018-01-01T16:59:00+00:00 https://razorgenomics.com/publications/adjuvant-chemotherapy-guided-by-molecular-profiling-and-improved-outcomes-in-early-stage-non-small-cell-lung-cancer/ 2018-01-01T17:00:00+00:00 https://razorgenomics.com/publications/incorporation-of-a-molecular-prognostic-classifier-improves-conventional-non-small-cell-lung-cancer-staging/ 2019-01-01T16:59:00+00:00 https://razorgenomics.com/publications/comparison-of-conventional-tnm-and-novel-tnmb-staging-systems-for-non-small-cell-lung-cancer/ 2019-01-01T17:00:00+00:00 https://razorgenomics.com/publications/everybody-must-get-scanned-molecular-risk-stratification-may-limit-the-need-for-ct-surveillance-following-surgical-resection-of-early-stage-non-squamous-non-small-cell-lung-cancer/ 2020-05-01T15:59:00+00:00 https://razorgenomics.com/publications/the-potential-of-a-clia-certified-prognostic-predictive-molecular-test-to-address-the-rising-costs-of-non-small-cell-lung-cancer/ 2026-07-31T19:25:05+00:00 https://razorgenomics.com/publications/molecular-risk-stratification-is-independent-of-egfr-mutation-status-in-identifying-early-stage-non-squamous-non-small-cell-lung-cancer-patients-at-risk-for-recurrence-and-likely-to-benefit-3/ 2026-07-31T19:26:59+00:00 https://razorgenomics.com/publications/adjuvant-chemotherapy-for-stage-iaiia-non-squamous-non-small-cell-lung-cancer-identified-as-molecular-high-risk-by-a-14-gene-expression-profile-aim-high-an-international-randomised-phase-3-t/ 2026-07-31T19:27:48+00:00 https://razorgenomics.com/publications/characterization-of-clinicopathologic-features-and-molecular-recurrence-risk-profiles-in-patients-with-early-stage-nsclc/ 2026-07-31T19:29:27+00:00 https://razorgenomics.com/publications/adjuvant-chemotherapy-for-stage-ia-iia-non-squamous-non-small-cell-lung-cancer-identified-as-molecular-high-risk-by-a-14-gene-expression-profile-aim-high-an-international-randomised-phase-3/ 2026-07-31T19:34:31+00:00 https://razorgenomics.com/publications/molecular-recurrence-risk-profiles-in-patients-with-early-stage-nsclc-current-standard-of-care-compared-to-a-prognostic-and-predictive-14-gene-expression-assay/ 2026-07-31T19:37:40+00:00 https://razorgenomics.com/publications/molecular-risk-stratification-is-independent-of-egfr-mutation-status-in-identifying-early-stage-non-squamous-non-small-cell-lung-cancer-patients-at-risk-for-recurrence-and-likely-to-benefit-2/ 2026-07-31T19:48:50+00:00 https://razorgenomics.com/publications/a-prognostic-assay-to-identify-patients-at-high-risk-of-mortality-despite-small-node-negative-lung-tumors/ 2026-07-31T19:51:00+00:00